Global Opioid Induced Constipation Market Research Report 2023(Status and Outlook)

Global Opioid Induced Constipation Market Research Report 2023(Status and Outlook)



Report Overview

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.

North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.

In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.

The Global Opioid Induced Constipation Market Size was estimated at USD 2415 million in 2022 and is projected to reach USD 3308.56 million by 2029, exhibiting a CAGR of 4.60% during the forecast period.

Bosson Research’s latest report provides a deep insight into the global Opioid Induced Constipation market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Opioid Induced Constipation Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Opioid Induced Constipation market in any manner.

Global Opioid Induced Constipation Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Takeda Pharmaceuticals

Bayer

Sanofi

Mallinckrodt

Salix (Bausch Health)

AstraZeneca

Progenics Pharmaceuticals

Purdue Pharm

Nektar Therapeutics

Daiichi Sankyo

Prestige

GSK

Shionogi

Market Segmentation (by Type)

Methylnaltrexone Bromide

Lubiprostone

Naloxegol

Others

Market Segmentation (by Application)

For 72 Hour Use

For 24 Hour Use

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Opioid Induced Constipation Market

Overview of the regional outlook of the Opioid Induced Constipation Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Opioid Induced Constipation
1.2 Key Market Segments
1.2.1 Opioid Induced Constipation Segment by Type
1.2.2 Opioid Induced Constipation Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Opioid Induced Constipation Market Overview
2.1 Global Market Overview
2.1.1 Global Opioid Induced Constipation Market Size (M USD) Estimates and Forecasts (2018-2029)
2.1.2 Global Opioid Induced Constipation Sales Estimates and Forecasts (2018-2029)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Opioid Induced Constipation Market Competitive Landscape
3.1 Global Opioid Induced Constipation Sales by Manufacturers (2018-2023)
3.2 Global Opioid Induced Constipation Revenue Market Share by Manufacturers (2018-2023)
3.3 Opioid Induced Constipation Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Opioid Induced Constipation Average Price by Manufacturers (2018-2023)
3.5 Manufacturers Opioid Induced Constipation Sales Sites, Area Served, Product Type
3.6 Opioid Induced Constipation Market Competitive Situation and Trends
3.6.1 Opioid Induced Constipation Market Concentration Rate
3.6.2 Global 5 and 10 Largest Opioid Induced Constipation Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Opioid Induced Constipation Industry Chain Analysis
4.1 Opioid Induced Constipation Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Opioid Induced Constipation Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Opioid Induced Constipation Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Opioid Induced Constipation Sales Market Share by Type (2018-2023)
6.3 Global Opioid Induced Constipation Market Size Market Share by Type (2018-2023)
6.4 Global Opioid Induced Constipation Price by Type (2018-2023)
7 Opioid Induced Constipation Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Opioid Induced Constipation Market Sales by Application (2018-2023)
7.3 Global Opioid Induced Constipation Market Size (M USD) by Application (2018-2023)
7.4 Global Opioid Induced Constipation Sales Growth Rate by Application (2018-2023)
8 Opioid Induced Constipation Market Segmentation by Region
8.1 Global Opioid Induced Constipation Sales by Region
8.1.1 Global Opioid Induced Constipation Sales by Region
8.1.2 Global Opioid Induced Constipation Sales Market Share by Region
8.2 North America
8.2.1 North America Opioid Induced Constipation Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Opioid Induced Constipation Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Opioid Induced Constipation Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Opioid Induced Constipation Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Opioid Induced Constipation Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Takeda Pharmaceuticals
9.1.1 Takeda Pharmaceuticals Opioid Induced Constipation Basic Information
9.1.2 Takeda Pharmaceuticals Opioid Induced Constipation Product Overview
9.1.3 Takeda Pharmaceuticals Opioid Induced Constipation Product Market Performance
9.1.4 Takeda Pharmaceuticals Business Overview
9.1.5 Takeda Pharmaceuticals Opioid Induced Constipation SWOT Analysis
9.1.6 Takeda Pharmaceuticals Recent Developments
9.2 Bayer
9.2.1 Bayer Opioid Induced Constipation Basic Information
9.2.2 Bayer Opioid Induced Constipation Product Overview
9.2.3 Bayer Opioid Induced Constipation Product Market Performance
9.2.4 Bayer Business Overview
9.2.5 Bayer Opioid Induced Constipation SWOT Analysis
9.2.6 Bayer Recent Developments
9.3 Sanofi
9.3.1 Sanofi Opioid Induced Constipation Basic Information
9.3.2 Sanofi Opioid Induced Constipation Product Overview
9.3.3 Sanofi Opioid Induced Constipation Product Market Performance
9.3.4 Sanofi Business Overview
9.3.5 Sanofi Opioid Induced Constipation SWOT Analysis
9.3.6 Sanofi Recent Developments
9.4 Mallinckrodt
9.4.1 Mallinckrodt Opioid Induced Constipation Basic Information
9.4.2 Mallinckrodt Opioid Induced Constipation Product Overview
9.4.3 Mallinckrodt Opioid Induced Constipation Product Market Performance
9.4.4 Mallinckrodt Business Overview
9.4.5 Mallinckrodt Opioid Induced Constipation SWOT Analysis
9.4.6 Mallinckrodt Recent Developments
9.5 Salix (Bausch Health)
9.5.1 Salix (Bausch Health) Opioid Induced Constipation Basic Information
9.5.2 Salix (Bausch Health) Opioid Induced Constipation Product Overview
9.5.3 Salix (Bausch Health) Opioid Induced Constipation Product Market Performance
9.5.4 Salix (Bausch Health) Business Overview
9.5.5 Salix (Bausch Health) Opioid Induced Constipation SWOT Analysis
9.5.6 Salix (Bausch Health) Recent Developments
9.6 AstraZeneca
9.6.1 AstraZeneca Opioid Induced Constipation Basic Information
9.6.2 AstraZeneca Opioid Induced Constipation Product Overview
9.6.3 AstraZeneca Opioid Induced Constipation Product Market Performance
9.6.4 AstraZeneca Business Overview
9.6.5 AstraZeneca Recent Developments
9.7 Progenics Pharmaceuticals
9.7.1 Progenics Pharmaceuticals Opioid Induced Constipation Basic Information
9.7.2 Progenics Pharmaceuticals Opioid Induced Constipation Product Overview
9.7.3 Progenics Pharmaceuticals Opioid Induced Constipation Product Market Performance
9.7.4 Progenics Pharmaceuticals Business Overview
9.7.5 Progenics Pharmaceuticals Recent Developments
9.8 Purdue Pharm
9.8.1 Purdue Pharm Opioid Induced Constipation Basic Information
9.8.2 Purdue Pharm Opioid Induced Constipation Product Overview
9.8.3 Purdue Pharm Opioid Induced Constipation Product Market Performance
9.8.4 Purdue Pharm Business Overview
9.8.5 Purdue Pharm Recent Developments
9.9 Nektar Therapeutics
9.9.1 Nektar Therapeutics Opioid Induced Constipation Basic Information
9.9.2 Nektar Therapeutics Opioid Induced Constipation Product Overview
9.9.3 Nektar Therapeutics Opioid Induced Constipation Product Market Performance
9.9.4 Nektar Therapeutics Business Overview
9.9.5 Nektar Therapeutics Recent Developments
9.10 Daiichi Sankyo
9.10.1 Daiichi Sankyo Opioid Induced Constipation Basic Information
9.10.2 Daiichi Sankyo Opioid Induced Constipation Product Overview
9.10.3 Daiichi Sankyo Opioid Induced Constipation Product Market Performance
9.10.4 Daiichi Sankyo Business Overview
9.10.5 Daiichi Sankyo Recent Developments
9.11 Prestige
9.11.1 Prestige Opioid Induced Constipation Basic Information
9.11.2 Prestige Opioid Induced Constipation Product Overview
9.11.3 Prestige Opioid Induced Constipation Product Market Performance
9.11.4 Prestige Business Overview
9.11.5 Prestige Recent Developments
9.12 GSK
9.12.1 GSK Opioid Induced Constipation Basic Information
9.12.2 GSK Opioid Induced Constipation Product Overview
9.12.3 GSK Opioid Induced Constipation Product Market Performance
9.12.4 GSK Business Overview
9.12.5 GSK Recent Developments
9.13 Shionogi
9.13.1 Shionogi Opioid Induced Constipation Basic Information
9.13.2 Shionogi Opioid Induced Constipation Product Overview
9.13.3 Shionogi Opioid Induced Constipation Product Market Performance
9.13.4 Shionogi Business Overview
9.13.5 Shionogi Recent Developments
10 Opioid Induced Constipation Market Forecast by Region
10.1 Global Opioid Induced Constipation Market Size Forecast
10.2 Global Opioid Induced Constipation Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Opioid Induced Constipation Market Size Forecast by Country
10.2.3 Asia Pacific Opioid Induced Constipation Market Size Forecast by Region
10.2.4 South America Opioid Induced Constipation Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Opioid Induced Constipation by Country
11 Forecast Market by Type and by Application (2024-2029)
11.1 Global Opioid Induced Constipation Market Forecast by Type (2024-2029)
11.1.1 Global Forecasted Sales of Opioid Induced Constipation by Type (2024-2029)
11.1.2 Global Opioid Induced Constipation Market Size Forecast by Type (2024-2029)
11.1.3 Global Forecasted Price of Opioid Induced Constipation by Type (2024-2029)
11.2 Global Opioid Induced Constipation Market Forecast by Application (2024-2029)
11.2.1 Global Opioid Induced Constipation Sales (K MT) Forecast by Application
11.2.2 Global Opioid Induced Constipation Market Size (M USD) Forecast by Application (2024-2029)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings